Organoids Services Market
Organoids are developed from stem cells, which are unbounded multiplicity cells that give rise to a variety of cell types in their offspring. To allow stem cells to follow their genetic fate and self-organize into tiny structures that resemble miniature organs, scientists have learned how to provide the correct conditions for the stem cells. Organoids can be as small as 5 mm, or they can be smaller than the breadth of a hair. The organoids services market report emphasizes key factors impacting the market and showcases the developments of prominent players.
The organoids services market in North America is expected to register a CAGR of 21.9% during 2023–2031. The region also dominates the global market in terms of share. Market players in the US are focusing on organic growth strategies to strengthen their foothold. In February 2023, Molecular Devices, LLC. and HUB Organoids (HUB) announced a strategic collaboration to continue the development of next-generation 3D biology technologies that drive step-change reduction in preclinical to clinical drug attrition. Further, increasing research and development activities, rising demand for tissue engineering and organ transplantation, and a high rate of organoid adoption are driving the organoid services market in the country. Organoids have the potential to overcome several previous limitations associated with biomedical research studies, with a high focus on making mechanistic insights on human development available for researchers, producing accurate models of human disease, and generating patient-matched tissue sources for regenerative medicine.
The Asia Pacific organoids services market is expected to record the fastest CAGR during 2023–2031. The projected market growth in the region during the forecast period is attributed to factors such as the increasing use of organoids, government efforts to raise awareness related to human organoids, supportive regulations for the development and commercialization of advanced human organoid products, and an upsurge in the funding for organoid research.
Increasing Demand for Innovative Drug Screening Services Bolsters Organoids Services Market Growth
Organoids are emerging as a powerful asset for researchers and drug developers as they seek more efficient and accurate methods to identify promising drug candidates and predict their efficacy. The ability to generate patient-derived organoids opens up exciting possibilities for personalized drug screening. Organoids serve as realistic and relevant models for drug screening compared to traditional 2D cell cultures. They mimic the complexity of human organs, including their cellular composition, structure, and function, providing a more accurate representation of drug responses in the human body. This enables researchers to identify potential drug candidates more confidently, and avoid costly and time-consuming failures in clinical trials. The organoid services market is experiencing rapid growth owing to the increasing demand for innovative screening services.
By creating organoids from a patient’s cells, researchers can tailor drug testing to individual responses, improving the probability of treatment success through a personalized approach. The integration of advanced technologies, such as high-throughput screening platforms and automated image analysis, further enhances the capabilities of organoid screening services. With the integration of high-throughput screening and organoids, researchers can test many drug compounds efficiently, analyze results more accurately, and accelerate the drug discovery process. Thus, the global focus on innovative screening services, driven by the popularity of personalized medicine and the need for faster drug development, favors the growth of the organoids services market. In January 2024, HUB Organoids (HUB) launched IntegriGut Screen for the global market. This innovative screening service employs patient-derived organoid (PDO) monolayers—-organoid monolayers derived from inflammatory bowel disease (IBD) patients—allowing access to high-quality human data on epithelial barrier function and accelerating the development of novel IBD therapies.
Organoids Services Market: Segment Overview
Based on type, the organoids services market is classified into intestine, liver, stomach, pancreas, lung, brain, kidney, and others. The intestine segment held the largest share of the market in 2023, and it is further anticipated to register the highest CAGR during the forecast period.
By application, the market is segmented into developmental biology, infectious disease pathology, regenerative medicine, drug toxicity & efficacy testing, drug discovery & personalized medicine, and others. The developmental biology segment held the largest share of the market in 2023; it is further anticipated to register the highest CAGR during 2023–2031.
Based on source, the organoids services market is divided into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger share of the market in 2023. The pluripotent stem cells segment is anticipated to register a higher CAGR during the forecast period.
Organoids Services Market: Competitive Landscape and Key Developments
Sino Biological Inc.; Eurofins Scientific SE; Molecular Devices, LLC.; InSphero; Cyprio; InnoSer; LABTOO; CUSABIO TECHNOLOGY LLC; Oncodesign Services; and HUB Organoids B.V. (Hubrecht Organoid Technology) are among the key companies operating in the organoids services market.
